Combination therapy for untreated marginal zone lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two drugs for people with a type of lymphoma called marginal zone lymphoma who have not had prior systemic treatment. It aims to see if the combination can shrink or control the cancer and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of marginal zone lymphoma (a type of B-cell lymphoma).
- You have not received systemic treatment (like chemotherapy) for this lymphoma before.
- You have at least one tumor that can be measured on scans.
- You are in a stage of the disease that requires treatment (such as having symptoms, low blood counts, bleeding, large masses, or rapid growth).
- You have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This trial tests a new combination of two drugs (ibrutinib and rituximab) for people with marginal zone lymphoma that has not responded to other treatments. The goal is to see if this combination can help shrink the lymphoma and improve outcomes.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
Hear when a new Marginal Zone Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.